Xilio Therapeutics, Inc.
$8.45
▲
0.35%
2026-04-21 10:21:01
xiliotx.com
NCM: XLO
Explore Xilio Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$49.46 M
Current Price
$8.45
52W High / Low
$16.52 / $6.47
Stock P/E
—
Book Value
$7.79
Dividend Yield
—
ROCE
-42.66%
ROE
-1.33%
Face Value
—
EPS
$-58.66
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
76
Beta
-0.12
Debt / Equity
19.71
Current Ratio
2.58
Quick Ratio
2.58
Forward P/E
-14.67
Price / Sales
1.12
Enterprise Value
$-81.37 M
EV / EBITDA
2.01
EV / Revenue
-1.86
Rating
None
Target Price
$20
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zura Bio Limited | $5.37 | — | $491.42 M | — | -74.11% | -52.49% | $7.44 / $0.98 | $1.38 |
| 2. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
| 3. | Catalyst Pharmaceuticals, Inc. | $26.07 | 14.85 | $3.18 B | — | 26.94% | 25.49% | $26.58 / $19.05 | $7.79 |
| 4. | Absci Corporation | $3.95 | — | $547.82 M | — | -64.8% | -62.5% | $5.23 / $2.24 | $1.25 |
| 5. | Celcuity Inc. | $120.09 | — | $5.8 B | — | -40.76% | -1.64% | $127.34 / $9.5 | $2.08 |
| 6. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 7. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 13.69 M | 19.07 M | 8.08 M | 2.93 M | 1.72 M |
| Operating Profit | -11.84 M | -1.93 M | -14.37 M | -13.85 M | -13.63 M |
| Net Profit | 10.36 M | -16.29 M | -15.84 M | -13.27 M | -13.09 M |
| EPS in Rs | 1.79 | -2.82 | -2.74 | -2.29 | -2.26 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 43.77 M | 6.34 M | 0 M | 0 M |
| Operating Profit | -41.98 M | -59.65 M | -79.13 M | -89.15 M |
| Net Profit | -35.04 M | -58.24 M | -76.4 M | -88.22 M |
| EPS in Rs | -6.06 | -10.07 | -13.21 | -15.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 154.69 M | 71.08 M | 60.93 M | 139.16 M |
| Total Liabilities | 119.41 M | 53.48 M | 24.1 M | 33.52 M |
| Equity | 35.27 M | 17.6 M | 36.83 M | 105.65 M |
| Current Assets | 145.03 M | 60.23 M | 48.13 M | 124.5 M |
| Current Liabilities | 56.27 M | 27.26 M | 15.96 M | 21.12 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.99 M | -18.38 M | -68.62 M | -75.72 M |
| Investing CF | -0.52 M | -0.04 M | -0.49 M | -1.87 M |
| Financing CF | 87.78 M | 29.2 M | -6.55 M | -0.07 M |
| Free CF | -5.51 M | -18.41 M | -69.11 M | -77.59 M |
| Capex | -0.52 M | -0.04 M | -0.49 M | -1.87 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 589.88% | — | — | — |
| Earnings Growth % | 39.84% | 23.77% | 13.4% | — |
| Profit Margin % | -80.05% | -918.05% | — | — |
| Operating Margin % | -95.92% | -940.18% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -92.4% | -914.27% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-03-16 | 1:0.0714286 |